Cue Biopharma (CUE) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $16.71, -10.50% vs the prior close of $18.67.
- Volume 105.19K shares, 0.4x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CUE slides 10.5% to $16.71, a 3-month low. Closed at $16.71, -10.50% vs the prior close of $18.67. Day range $16.54–$18.87, opened at $18.57.
CUE daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — CUE slides 10.5% to $16.71, a 3-month low
- Closed at $16.71, -10.50% vs the prior close of $18.67. Day range $16.54–$18.87, opened at $18.57.
- Volume was 105.19K shares, 0.4x its 50-day average of 299.13K — lighter than usual.
- Price is -38.9% vs its 50-day average ($27.35) and -19.4% vs its 200-day average ($20.74).
- 52-week range $4.98–$45.50; today's close sits at 29% of that range, 63.3% below the 52-week high.
Oct 15, 2026 — CUE rises 0.4% to $18.67
- Closed at $18.67, +0.38% vs the prior close of $18.60. Day range $17.25–$18.98, opened at $18.53.
- Volume was 229.10K shares, 0.8x its 50-day average of 297.13K.
- Price is -32.3% vs its 50-day average ($27.56) and -9.8% vs its 200-day average ($20.70).
- 52-week range $4.98–$45.50; today's close sits at 34% of that range, 59.0% below the 52-week high.
Oct 14, 2026 — CUE slides 5.0% to $18.60, a 3-month low, 3 down days in a row
- Closed at $18.60, -4.96% vs the prior close of $19.57. Day range $18.09–$20.78, opened at $20.01.
- Volume was 245.00K shares, 0.8x its 50-day average of 295.98K.
- Price is -32.9% vs its 50-day average ($27.72) and -9.9% vs its 200-day average ($20.65).
- 52-week range $4.98–$45.50; today's close sits at 34% of that range, 59.1% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — CUE slides 20.5% to $19.57, a 3-month low
- Closed at $19.57, -20.48% vs the prior close of $24.61. Day range $19.50–$25.42, opened at $24.40.
- Volume was 301.30K shares, 1.0x its 50-day average of 292.78K.
- Price is -29.8% vs its 50-day average ($27.88) and -5.0% vs its 200-day average ($20.60).
- 52-week range $4.98–$45.50; today's close sits at 36% of that range, 57.0% below the 52-week high.
Oct 12, 2026 — CUE slides 11.0% to $24.61
- Closed at $24.61, -11.03% vs the prior close of $27.66. Day range $24.48–$29.00, opened at $27.44.
- Volume was 179.40K shares, 0.6x its 50-day average of 298.69K.
- Price is -12.2% vs its 50-day average ($28.02) and +19.8% vs its 200-day average ($20.54).
- 52-week range $4.98–$45.50; today's close sits at 48% of that range, 45.9% below the 52-week high.
Oct 9, 2026 — CUE jumps 23.9% to $27.66
- Closed at $27.66, +23.87% vs the prior close of $22.33. Day range $22.10–$29.00, opened at $22.21.
- Volume was 394.50K shares, 1.3x its 50-day average of 296.15K.
- Price is -1.5% vs its 50-day average ($28.07) and +35.2% vs its 200-day average ($20.45).
- 52-week range $4.98–$45.50; today's close sits at 56% of that range, 39.2% below the 52-week high.
Oct 8, 2026 — CUE dips 0.8% to $22.33, a 3-month low, 4 down days in a row
- Closed at $22.33, -0.80% vs the prior close of $22.51. Day range $21.60–$22.74, opened at $22.38.
- Volume was 109.90K shares, 0.4x its 50-day average of 295.96K — lighter than usual.
- Price is -20.6% vs its 50-day average ($28.12) and +9.7% vs its 200-day average ($20.35).
- 52-week range $4.98–$45.50; today's close sits at 43% of that range, 50.9% below the 52-week high.
- That makes 4 straight losses.
Oct 7, 2026 — CUE dips 2.7% to $22.51, a 3-month low, 3 down days in a row
- Closed at $22.51, -2.72% vs the prior close of $23.14. Day range $22.27–$23.10, opened at $22.92.
- Volume was 133.10K shares, 0.4x its 50-day average of 297.34K — lighter than usual.
- Price is -20.3% vs its 50-day average ($28.24) and +11.0% vs its 200-day average ($20.28).
- 52-week range $4.98–$45.50; today's close sits at 43% of that range, 50.5% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — CUE slides 5.0% to $23.14, a 3-month low
- Closed at $23.14, -5.01% vs the prior close of $24.36. Day range $22.92–$24.89, opened at $24.22.
- Volume was 174.80K shares, 0.6x its 50-day average of 298.50K — lighter than usual.
- Price is -18.5% vs its 50-day average ($28.39) and +14.4% vs its 200-day average ($20.22).
- 52-week range $4.98–$45.50; today's close sits at 45% of that range, 49.1% below the 52-week high.
Oct 5, 2026 — CUE slides 4.7% to $24.36, a 1-month low
- Closed at $24.36, -4.73% vs the prior close of $25.57. Day range $22.21–$25.94, opened at $25.60.
- Volume was 272.60K shares, 0.9x its 50-day average of 296.02K.
- Price is -14.8% vs its 50-day average ($28.58) and +20.8% vs its 200-day average ($20.17).
- 52-week range $4.98–$45.50; today's close sits at 48% of that range, 46.5% below the 52-week high.
Oct 2, 2026 — CUE rises 1.3% to $25.57
- Closed at $25.57, +1.27% vs the prior close of $25.25. Day range $24.67–$25.92, opened at $25.60.
- Volume was 156.90K shares, 0.5x its 50-day average of 295.28K — lighter than usual.
- Price is -11.0% vs its 50-day average ($28.74) and +27.2% vs its 200-day average ($20.11).
- 52-week range $4.98–$45.50; today's close sits at 51% of that range, 43.8% below the 52-week high.
CUE latest news & SEC filings
Every SEC filing by or about CUE in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ray Sumita sold 1,844 shares at $28.05 (≈$51.72K) on Oct 12, 2026; now holds 116,701
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Meluzio Michael Vincent sold 1,144 shares at $28.05 (≈$32.09K) on Oct 12, 2026; now holds 47,817
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Lin Shao-Lee sold 10,000 shares at $27.50 (≈$275.00K) on Oct 12, 2026; now holds 695,995
- Lin Shao-Lee sold 1,087 shares at $28.05 (≈$30.49K) on Oct 12, 2026; now holds 694,908
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 13, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 13, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 8, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 28, 2026 · Form 4/A — Insider trade (amended)
Amended insider trade report (Form 4/A)
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 21, 2026 · Form SCHEDULE 13D — Activist-style stake (13D)
Activist-style stake (13D) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 20, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Aug 18, 2026 · Form CORRESP — Company letter to the SEC
Company letter to the SEC
Aug 17, 2026 · Form UPLOAD — SEC staff letter to the company
SEC staff letter to the company
Aug 14, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $7.88M (prior year $2.95M) (+166.7% vs Jun 30, 2025)
- Net income: -$153.07M (prior year -$8.48M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$24.14 (prior year -$2.67) (loss widened vs Jun 30, 2025)
Aug 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade CUE
- Last results release: Aug 14, 2026 (8-K Item 2.02). Previous ones: Mar 16, 2026, Nov 12, 2025, Aug 12, 2025. Based on that rhythm, the next report is likely around Nov 13, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 7.64% (largest 23.9%). That is a volatile stock.
- Liquidity: about 461.50K shares (≈$7.71M) trade per day on average.
- 52-week position: $16.71 vs a range of $4.98–$45.50 (29% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:30 on Apr 24, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Michael Vincent Meluzio sold 3 shares on Aug 13, 2026.
- Latest filings: 8-K Sep 21, 2026; 10-Q Aug 14, 2026; 8-K Aug 14, 2026.
- Share count: 7.26M shares outstanding (Aug 12, 2026), -90.5% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
CUE market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 18.57 | 18.87 | 16.54 | 16.71 | 105.19K |
| Oct 15, 2026 | 18.53 | 18.98 | 17.25 | 18.67 | 229.10K |
| Oct 14, 2026 | 20.01 | 20.78 | 18.09 | 18.60 | 245.00K |
| Oct 13, 2026 | 24.40 | 25.42 | 19.50 | 19.57 | 301.30K |
| Oct 12, 2026 | 27.44 | 29.00 | 24.48 | 24.61 | 179.40K |
| Oct 9, 2026 | 22.21 | 29.00 | 22.10 | 27.66 | 394.50K |
| Oct 8, 2026 | 22.38 | 22.74 | 21.60 | 22.33 | 109.90K |
| Oct 7, 2026 | 22.92 | 23.10 | 22.27 | 22.51 | 133.10K |
| Oct 6, 2026 | 24.22 | 24.89 | 22.92 | 23.14 | 174.80K |
| Oct 5, 2026 | 25.60 | 25.94 | 22.21 | 24.36 | 272.60K |
| Oct 2, 2026 | 25.60 | 25.92 | 24.67 | 25.57 | 156.90K |
| Oct 1, 2026 | 26.00 | 26.02 | 24.60 | 25.25 | 183.40K |
| Sep 30, 2026 | 25.89 | 27.43 | 24.88 | 25.87 | 228.10K |
| Sep 29, 2026 | 28.15 | 28.15 | 24.13 | 25.51 | 283.80K |
| Sep 28, 2026 | 30.86 | 32.07 | 27.01 | 27.45 | 237.70K |
| Sep 25, 2026 | 33.12 | 33.40 | 30.75 | 31.41 | 232.40K |
| Sep 24, 2026 | 31.15 | 33.63 | 30.43 | 32.85 | 330.40K |
| Sep 23, 2026 | 29.91 | 35.23 | 29.86 | 31.71 | 696.40K |
| Sep 22, 2026 | 28.61 | 32.39 | 25.49 | 30.90 | 1.21M |
| Sep 21, 2026 | 38.50 | 41.50 | 23.80 | 28.27 | 3.53M |
About Cue Biopharma
Cue Biopharma (CUE) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SOMERVILLE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1645460.
CUE board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Usman Azam | CHIEF EXECUTIVE OFFICER | Oct 2, 2025 |
| Jill Marie Broadfoot | Director | Jan 6, 2026 |
| Daniel A. Camardo | Director | Jul 10, 2026 |
| Pamela Garzone | Director | Aug 28, 2026 |
| Peter A Kiener | Director | Jan 6, 2026 |
| Shao-Lee Lin | Chief Executive Officer | Aug 14, 2026 |
| Viola Mong Meehan | Director | Jul 10, 2026 |
| Frank Morich | Director | Jan 6, 2026 |
| Pasha Sarraf | Director | Aug 28, 2026 |
| Patrick Verheyen | Director | Jan 6, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| James M Ahlers | Chief Financial Officer | Aug 3, 2026 |
| Usman Azam | CHIEF EXECUTIVE OFFICER | Oct 2, 2025 |
| Daniel G. Baker | CHIEF DEVELOPMENT OFFICER | Apr 10, 2026 |
| Dominique Christian Borie | Chief Medical Officer | Jul 15, 2026 |
| Shao-Lee Lin | Chief Executive Officer | Aug 14, 2026 |
| Michael Vincent Meluzio | VP, Prin. Accounting Officer | Aug 17, 2026 |
| Sumita Ray | Chief Legal Compliance Officer | Aug 17, 2026 |
| Colin Sandercock | SVP, GENERAL COUNSEL | Apr 10, 2026 |
| Lucinda Warren | CHIEF BUSINESS OFFICER | Apr 10, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 13, 2026 | Michael Vincent Meluzio | Sale | 3 | $31.13 |
| Aug 13, 2026 | Michael Vincent Meluzio | Sale | 4,106 | $30.35 |
| Aug 13, 2026 | Michael Vincent Meluzio | Sale | 1,519 | $29.37 |
| Aug 13, 2026 | Michael Vincent Meluzio | Sale | 3 | $31.13 |
| Aug 13, 2026 | Michael Vincent Meluzio | Sale | 4,106 | $30.35 |
| Aug 13, 2026 | Michael Vincent Meluzio | Sale | 1,519 | $29.37 |
| Aug 13, 2026 | Michael Vincent Meluzio | Sale | 3 | $31.13 |
| Aug 13, 2026 | Michael Vincent Meluzio | Sale | 4,106 | $30.35 |
| Aug 13, 2026 | Michael Vincent Meluzio | Sale | 1,519 | $29.37 |
| Aug 13, 2026 | Michael Vincent Meluzio | Sale | 3 | $31.13 |
| Aug 13, 2026 | Michael Vincent Meluzio | Sale | 4,106 | $30.35 |
| Aug 13, 2026 | Michael Vincent Meluzio | Sale | 1,519 | $29.37 |
| Aug 13, 2026 | Sumita Ray | Sale | 2,383 | $29.37 |
| Aug 13, 2026 | Sumita Ray | Sale | 6,442 | $30.35 |
| Aug 13, 2026 | Sumita Ray | Sale | 4 | $31.13 |
CUE financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $27.47M | $-26.60M | -0.28 | $-21.69M |
| Dec 31, 2024 | $9.29M | $-40.67M | -0.72 | $-36.33M |
| Dec 31, 2023 | $5.49M | $-50.73M | -1.11 | $-39.96M |
| Dec 31, 2022 | $1.25M | $-53.01M | -1.49 | $-41.81M |
| Dec 31, 2021 | $14.94M | $-44.16M | -1.41 | $-38.84M |
Latest balance sheet: total assets $30.71M, total liabilities $28.40M, cash $17.39M (as of Jun 30, 2026).
CUE earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 14, 2026 | 8-K Item 2.02 (results) | $34.20 |
| Mar 16, 2026 | 8-K Item 2.02 (results) | $9.36 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $20.04 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $23.70 |
| May 12, 2025 | 8-K Item 2.02 (results) | $22.53 |
| Apr 15, 2025 | 8-K Item 2.02 (results) | $24.00 |
| Mar 31, 2025 | 8-K Item 2.02 (results) | $27.33 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $45.00 |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| May 19, 2020 | 8-K Item 2.02 (results) | — |
| Mar 17, 2020 | 8-K Item 2.02 (results) | — |
| Nov 12, 2019 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on CUE
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.